Yuhan Licenses Out Degenerative Disc Therapy To Spine Despite Earlier Trial Failure

Yuhan Corp. has licensed out its investigative degenerative disc therapy YH14618 to US-based Spine Biopharma LLC in a deal worth up to $218m plus sales royalties, reviving the compound after the leading South Korean pharma company halted clinical development after failure in a Phase II Korean study in 2016.

Under the new agreement, Spine Biopharma will proceed with development, approval, manufacturing and commercialization of the compound in global markets, while Yuhan will retain its sales rights in South Korea. Yuhan will receive $650,000 upfront and $217